Title: <scp>SARS‐CoV</scp>‐2: At the Crossroad Between Aging and Neurodegeneration
Abstract: Movement DisordersVolume 35, Issue 5 p. 716-720 Viewpoint SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration Alice Lippi MSc, Alice Lippi MSc Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany Center of Excellence for Science and Technology-Integration of Mediterranean Region (STIM), Faculty of Science, University of Split, Split, CroatiaSearch for more papers by this authorRenato Domingues MSc, Renato Domingues MSc Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, GermanySearch for more papers by this authorCristian Setz MD, Cristian Setz MD Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany Department of Otolaryngology-Head and Neck Surgery, University Medical Center Goettingen, Goettingen, GermanySearch for more papers by this authorTiago F. Outeiro PhD, Corresponding Author Tiago F. Outeiro PhD [email protected] orcid.org/0000-0003-1679-1727 Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany Max Planck Institute for Experimental Medicine, Goettingen, Germany Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne, United KingdomCorrespondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this authorAnita Krisko PhD, Corresponding Author Anita Krisko PhD [email protected] Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, GermanyCorrespondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this author Alice Lippi MSc, Alice Lippi MSc Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany Center of Excellence for Science and Technology-Integration of Mediterranean Region (STIM), Faculty of Science, University of Split, Split, CroatiaSearch for more papers by this authorRenato Domingues MSc, Renato Domingues MSc Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, GermanySearch for more papers by this authorCristian Setz MD, Cristian Setz MD Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany Department of Otolaryngology-Head and Neck Surgery, University Medical Center Goettingen, Goettingen, GermanySearch for more papers by this authorTiago F. Outeiro PhD, Corresponding Author Tiago F. Outeiro PhD [email protected] orcid.org/0000-0003-1679-1727 Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, Germany Max Planck Institute for Experimental Medicine, Goettingen, Germany Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne, United KingdomCorrespondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this authorAnita Krisko PhD, Corresponding Author Anita Krisko PhD [email protected] Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center, Goettingen, Goettingen, GermanyCorrespondence to: Dr. Anita Krisko, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]; or Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, Waldweg 33, 37077 Goettingen, Germany; E-mail: [email protected]Search for more papers by this author First published: 15 April 2020 https://doi.org/10.1002/mds.28084Citations: 106 Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579: 265–269. 10.1038/s41586-020-2008-3 CASPubMedWeb of Science®Google Scholar 2Chen X, Yu B. First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Glob Health Res Policy 2020; 5: 7. 10.1186/s41256-020-00137-4 PubMedGoogle Scholar 3Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–1976. 10.1056/NEJMoa030747 CASPubMedWeb of Science®Google Scholar 4Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814–1820. 10.1056/NEJMoa1211721 CASPubMedWeb of Science®Google Scholar 5Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382: 1199–207. 10.1056/NEJMoa2001316 CASPubMedWeb of Science®Google Scholar 6Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res 2018; 100: 163–188. 10.1016/bs.aivir.2018.01.001 CASPubMedWeb of Science®Google Scholar 7Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24: 490–502. 10.1016/j.tim.2016.03.003 CASPubMedWeb of Science®Google Scholar 8de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14: 523–534. 10.1038/nrmicro.2016.81 CASPubMedWeb of Science®Google Scholar 9Menachery VD, Eisfeld AJ, Schäfer A, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio 2014; 5: e01174-14. 10.1128/mBio.01174-14 PubMedWeb of Science®Google Scholar 10Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. biorxiv 2020.03.22.002386v1. [Preprint]. Google Scholar 11Reineke LC, Lloyd RE. The stress granule protein G3BP1 recruits protein kinase R to promote multiple innate immune antiviral responses. J Virol 2015; 89: 2575–2589. 10.1128/JVI.02791-14 CASPubMedWeb of Science®Google Scholar 12Yang W, Ru Y, Ren J, et al. G3BP1 inhibits RNA virus replication by positively regulating RIG-I-mediated cellular antiviral response. Cell Death Dis 2019; 10: 946. 10.1038/s41419-019-2178-9 CASPubMedWeb of Science®Google Scholar 13Kim SSY, Sze L, Lam KP. The stress granule protein G3BP1 binds viral dsRNA and RIG-I to enhance interferon-β response. J Biol Chem 2019; 294: 6430–6438. 10.1074/jbc.RA118.005868 CASPubMedWeb of Science®Google Scholar 14Raaben M, Groot Koerkamp MJA, Rottier PJM, de Haan CAM. Mouse hepatitis coronavirus replication induces host translational shutoff and mRNA decay, with concomitant formation of stress granules and processing bodies. Cell Microbiol 2007; 9: 2218–2229. 10.1111/j.1462-5822.2007.00951.x CASPubMedWeb of Science®Google Scholar 15López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194–1217. 10.1016/j.cell.2013.05.039 CASPubMedWeb of Science®Google Scholar 16Cao M, Wei C, Zhao L, et al. DnaJA1/Hsp40 is co-opted by influenza a virus to enhance its viral RNA polymerase activity. J Virol 2014; 88: 14078–14089. 10.1128/JVI.02475-14 PubMedWeb of Science®Google Scholar 17Sharma K, Tripathi S, Ranjan P, et al. Influenza A virus nucleoprotein exploits Hsp40 to inhibit PKR activation. PLoS One 2011; 6:e20215. 10.1371/journal.pone.0020215 CASPubMedWeb of Science®Google Scholar 18Batra J, Tripathi S, Kumar A, et al. Human heat shock protein 40 (Hsp40/DnaJB1) promotes influenza A virus replication by assisting nuclear import of viral ribonucleoproteins. Sci Rep 2016; 6: 19063. 10.1038/srep19063 CASPubMedWeb of Science®Google Scholar 19Hirayama E, Atagi H, Hiraki A, Kim J. Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex. J Virol. 2004; 78: 1263–70. 10.1128/JVI.78.3.1263-1270.2004 CASPubMedWeb of Science®Google Scholar 20Manzoor R, Kuroda K, Yoshida R, Tsuda Y, Fujikura D, Miyamoto H, et al. Heat shock protein 70 modulates influenza A virus polymerase activity. J Biol Chem. 2014; 289: 7599–614. 10.1074/jbc.M113.507798 CASPubMedWeb of Science®Google Scholar 21Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, Nagata K. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J Biol Chem 2002; 277: 45306–45314. 10.1074/jbc.M206822200 CASPubMedWeb of Science®Google Scholar 22Naito T, Momose F, Kawaguchi A, Nagata K. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol 2007; 81: 1339–1349. 10.1128/JVI.01917-06 CASPubMedWeb of Science®Google Scholar 23Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469–475. 10.1038/35019501 CASPubMedWeb of Science®Google Scholar 24Pandey P. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19: 4310–4322. 10.1093/emboj/19.16.4310 CASPubMedWeb of Science®Google Scholar 25Chan CP, Siu KL, Chin KT, Yuen KY, Zheng B, Jin DY. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2006; 80: 9279–9287. 10.1128/JVI.00659-06 CASPubMedWeb of Science®Google Scholar 26Levine B. Eating oneself and uninvited guests. Cell 2005; 120: 159–162. CASPubMedWeb of Science®Google Scholar 27Marreiros R, Müller-Schiffmann A, Trossbach SV, et al. Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation. Proc Natl Acad Sci U S A 2020; 117: 6741–6751. 10.1073/pnas.1906466117 CASPubMedWeb of Science®Google Scholar 28Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy 2014; 10: 1426–1441. 10.4161/auto.29309 CASPubMedWeb of Science®Google Scholar 29Shi CS, Qi HY, Boularan C, et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol 2014; 193: 3080–3089. 10.4049/jimmunol.1303196 CASPubMedWeb of Science®Google Scholar 30Gack MU, Albrecht RA, Urano T, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009; 5: 439–449. 10.1016/j.chom.2009.04.006 CASPubMedWeb of Science®Google Scholar 31Widjaja I, de Vries E, Tscherne DM, Garcia-Sastre A, Rottier PJM, de Haan CAM. Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step. J Virol 2010; 84: 9625–9631. 10.1128/JVI.01048-10 CASPubMedWeb of Science®Google Scholar 32Liu XD, Ko S, Xu Y, et al. Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 2012; 287: 19687–19698. 10.1074/jbc.M112.350934 CASPubMedWeb of Science®Google Scholar 33Ye Z, Wong CK, Li P, Xie Y. A SARS-CoV protein, ORF-6, induces caspase-3 mediated, ER stress and JNK-dependent apoptosis. Biochim Biophys Acta 2008;1780: 1383–1387. Google Scholar 34Li S, Min JY, Krug RM, Sen GC. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 2006; 349: 13–21. 10.1016/j.virol.2006.01.005 CASPubMedWeb of Science®Google Scholar 35Grelak RP, Clark R, Stump JM, Vernier VG. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science 1970; 169: 203–204. 10.1126/science.169.3941.203 CASPubMedWeb of Science®Google Scholar 36Bauer RB, McHenry JT. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Neurology 1974; 24: 715–720. 10.1212/WNL.24.8.715 CASPubMedWeb of Science®Google Scholar 37Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm Suppl 1995; 46: 399–405. CASPubMedGoogle Scholar 38Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580–584. 10.1056/NEJM198209023071002 CASPubMedWeb of Science®Google Scholar 39Blake GJ. Amantadine for influenza A. Nursing 1990; 20: 21. 10.1097/00152193-199012000-00010 CASPubMedGoogle Scholar 40Kadowaki T, Komagamine T, Suzuki K, Hirata K. Oseltamivir-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 133–134. 10.1016/j.parkreldis.2010.10.013 PubMedWeb of Science®Google Scholar 41Toovey S, Jick SS, Meier CR. Parkinson's disease or Parkinson symptoms following seasonal influenza: influenza and Parkinson's disease. Influenza Other Respir Viruses 2011; 5: 328–333. 10.1111/j.1750-2659.2011.00232.x PubMedWeb of Science®Google Scholar 42Allen Reish HE, Standaert DG. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 2015; 5: 1–19. 10.3233/JPD-140491 CASPubMedWeb of Science®Google Scholar 43Roodveldt C, Labrador-Garrido A, Izquierdo G, Pozo D. Alpha-synuclein and the immune response in Parkinson's disease. In: Finkelstein D, ed. Towards New Therapies for Parkinson's Disease [Internet]. InTech; 2011 [cited 2020 Apr 3]. Available from: http://www.intechopen.com/books/towards-new-therapies-for-parkinson-s-disease/alpha-synuclein-and-the-immune-response-in-parkinson-s-disease. . Google Scholar 44Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 1992; 7: 153–158. 10.1002/mds.870070210 CASPubMedWeb of Science®Google Scholar 45Yamada T. Viral etiology of Parkinson's disease: focus on influenza A virus. Parkinsonism Relat Disord 1996; 2: 113–121. 10.1016/1353-8020(96)00006-5 CASPubMedGoogle Scholar 46Beatman EL, Massey A, Shives KD, et al. Alpha-synuclein expression restricts RNA viral infections in the brain. J Virol 2016; 90: 2767–2782. 10.1128/JVI.02949-15 CASWeb of Science®Google Scholar 47Shutinoski B, Hakimi M, Harmsen IE, et al. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci Transl Med 2019;11:eaas9292. 10.1126/scitranslmed.aas9292 PubMedWeb of Science®Google Scholar 48Hakimi M, Selvanantham T, Swinton E, et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011; 118: 795–808. 10.1007/s00702-011-0653-2 CASPubMedWeb of Science®Google Scholar Citing Literature Volume35, Issue5May 2020Pages 716-720 This article also appears in:Special Collection: COVID-19 Resources ReferencesRelatedInformation